The 6th Annual Oligonucleotides for CNS Summit USA returns to Boston on 19–21 August 2026, uniting 160+ leaders across pharma and biotech to accelerate the discovery, translation and clinical success of CNS‑targeted oligonucleotide therapies. As advances in RNA chemistry, delivery technologies and clinical evidence unlock previously undruggable CNS targets, this meeting is the industry’s most focused forum to benchmark what is truly working — and what’s next.

Across three highly interactive days, hear the latest data and strategy from companies including Eli Lilly, Stoke Therapeutics, Dyne Therapeutics, Creyon Bio and Quiver Bioscience, covering ASOs, siRNAs, saRNAs and aptamers. Dive into real‑world challenges around CNS penetration, BBB shuttles, intrathecal vs systemic delivery, splice modulation, chemistry and conjugation design, PK/PD translation, safety and regulatory alignment — all through case studies, panels, workshops and roundtables designed for open, precompetitive discussion.

With expanding pipelines, growing competition and rising expectations for clinical impact beyond rare disease, this summit offers a uniquely concentrated environment to learn from clinical‑stage programs, stress‑test your development strategy and connect with the scientists and decision‑makers shaping the future of CNS oligonucleotides.

Find out more today – https://ter.li/twgv2av6